tbuckley/cabot-search huggingface dataset:
Gamma entrainment using audiovisual stimuli alleviates chemobrain pathology and cognitive impairment induced by chemotherapy in mice
Authors: TaeHyun Kim, Benjamin T. James, Martin C. Kahn, Cristina Blanco-Duque, Fatema Abdurrob, Md Rezaul Islam, Nicolas S. Lavoie, Manolis Kellis, Li-Huei Tsai
Journal: Science Translational Medicine (2024)

Patients with cancer undergoing chemotherapy frequently experience a neurological condition known as chemotherapy-related cognitive impairment, or “chemobrain,” which can persist for the remainder of their lives. Despite the growing prevalence of chemobrain, both its underlying mechanisms and treatment strategies remain poorly understood. Recent findings suggest that chemobrain shares several characteristics with neurodegenerative diseases, including chronic neuroinflammation, DNA damage, and synaptic loss. We investigated whether a noninvasive sensory stimulation treatment we term gamma entrainment using sensory stimuli (GENUS), which has been shown to alleviate aberrant immune and synaptic pathologies in mouse models of neurodegeneration, could also mitigate chemobrain phenotypes in mice administered a chemotherapeutic drug. When administered concurrently with the chemotherapeutic agent cisplatin, GENUS alleviated cisplatin-induced brain pathology, promoted oligodendrocyte survival, and improved cognitive function in a mouse model of chemobrain. These effects persisted for up to 105 days after GENUS treatment, suggesting the potential for long-lasting benefits. However, when administered to mice 90 days after chemotherapy, GENUS treatment only provided limited benefits, indicating that it was most effective when used to prevent the progression of chemobrain pathology. Furthermore, we demonstrated that the effects of GENUS in mice were not limited to cisplatin-induced chemobrain but also extended to methotrexate-induced chemobrain. Collectively, these findings suggest that GENUS may represent a versatile approach for treating chemobrain induced by different chemotherapy agents.
B cell depletion with anti-CD20 promotes neuroprotection in a BAFF-dependent manner in mice and humans
Authors: Angela A. Wang, Felix Luessi, Tradite Neziraj, Elisabeth Pössnecker, Michelle Zuo, Sinah Engel, Nicholas Hanuscheck, Alexandra Florescu, Eryn Bugbee, Xianjie I. Ma, Fatima Rana, Dennis Lee, Lesley A. Ward, Jens Kuhle, Johannes Himbert, Muriel Schraad, Erwin van Puijenbroek, Christian Klein, Eduard Urich, Valeria Ramaglia, Anne-Katrin Pröbstel, Frauke Zipp, Jennifer L. Gommerman
Journal: Science Translational Medicine (2024)

Anti-CD20 therapy to deplete B cells is highly efficacious in preventing new white matter lesions in patients with relapsing-remitting multiple sclerosis (RRMS), but its protective capacity against gray matter injury and axonal damage is unclear. In a passive experimental autoimmune encephalomyelitis (EAE) model whereby T H 17 cells promote brain leptomeningeal immune cell aggregates, we found that anti-CD20 treatment effectively spared myelin content and prevented myeloid cell activation, oxidative damage, and mitochondrial stress in the subpial gray matter. Anti-CD20 treatment increased B cell survival factor (BAFF) in the serum, cerebrospinal fluid, and leptomeninges of mice with EAE. Although anti-CD20 prevented gray matter demyelination, axonal loss, and neuronal atrophy, co-treatment with anti-BAFF abrogated these benefits. Consistent with the murine studies, we observed that elevated BAFF concentrations after anti-CD20 treatment in patients with RRMS were associated with better clinical outcomes. Moreover, BAFF promoted survival of human neurons in vitro. Together, our data demonstrate that BAFF exerts beneficial functions in MS and EAE in the context of anti-CD20 treatment.
Deep learning for 3D biliary anatomy for living liver donor hepatectomy planning
Authors: Burcin Ekser, Akin Tekin, Deniz Balci
Journal: International Journal of Surgery (2024)

aDepartment of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA bDeWitt Daughtry Family Department of Surgery, University of Miami School of Medicine; Miami, FL, USA cDepartment of Surgery and Solid Organ Transplantation, Bahcesehir University School of Medicine, Istanbul, Turkiye KEYWORDS: biliary anatomy, liver transplantation, liver resection, hepatectomy, deep learning, 3D structure. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article. Published online ■ ■ *Corresponding author. Address: Department of Surgery, Indiana University School of Medicine, 550 University Blvd, Room 4601, Indianapolis, IN, USA. Tel: +317-944-4370; fax: +317-948-3268. E-mail address: [email protected] (B. Ekser). This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/
AI-Defined Cardiac Anatomy Improves Risk Stratification of Hybrid Perfusion Imaging
Authors: Robert J.H. Miller, Aakash Shanbhag, Aditya Killekar, Mark Lemley, Bryan Bednarski, Paul B. Kavanagh, Attila Feher, Edward J. Miller, Timothy Bateman, Valerie Builoff, Joanna X. Liang, David E. Newby, Damini Dey, Daniel S. Berman, Piotr J. Slomka
Journal: JACC. Cardiovascular imaging (2024)
A Single-Arm Phase 2 Trial of Trametinib in Patients with Locally Advanced or Metastatic Epithelioid Hemangioendothelioma
Authors: Scott M. Schuetze, Karla V. Ballman, Rachel Heise, Kristen N. Ganjoo, Elizabeth J. Davis, Suzanne George, Melissa A. Burgess, Edwin Choy, Dale R. Shepard, Gabriel Tinoco, Angela Hirbe, Ciara M. Kelly, Steven Attia, Hari A. Deshpande, Gary K. Schwartz, Brittany L. Siontis, Richard F. Riedel, Margaret von Mehren, Erin Kozlowski, Helen X. Chen, Caroline Astbury, Brian P. Rubin
Journal: Clinical Cancer Research (2024)

Epithelioid hemangioendothelioma (EHE) is a rare vascular cancer with pathogenic TAZ-CAMTA1 (calmodulinbinding transcription activator 1) operating as an oncogenic driver through activation of the MAPK pathway. Trametinib is an inhibitor of MEK, a critical kinase in the MAPK pathway. We sought to evaluate the effect of trametinib in patients with EHE.
Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension
Authors: Georg Semmler, Lukas Hartl, Yuly Paulin Mendoza, Benedikt Simbrunner, Mathias Jachs, Lorenz Balcar, Michael Schwarz, Benedikt Silvester Hofer, Laurenz Fritz, Anna Schedlbauer, Katharina Stopfer, Daniela Neumayer, Jurij Maurer, Robin Szymanski, Elias Laurin Meyer, Bernhard Scheiner, Peter Quehenberger, Michael Trauner, Elmar Aigner, Annalisa Berzigotti, Thomas Reiberger, Mattias Mandorfer
Journal: Hepatology (2024)

Compensated advanced chronic liver disease (cACLD) identifies patients at risk for clinically significant portal hypertension (CSPH), and thus, for liver-related complications. The limited availability of liver stiffness measurements (LSM) impedes the identification of patients at risk for cACLD/CSPH outside of specialized clinics. We aimed to develop a blood-based algorithm to identify cACLD by fibrosis-4 (FIB-4) and CSPH by von Willebrand factor/platelet count ratio (VITRO).
A commentary on ‘Comparison of risk of complication between neuraxial anaesthesia and general anaesthesia for hip fracture surgery: a systematic review and meta-analysis’
Authors: Xueli He, Lan Shen, Zhigang Zhang, Kai Yu, Jinye Shang, Zhicong Zhou, Gang Ma
Journal: International Journal of Surgery (2024)

He, Xueli MM; Shen, Lan MM; Zhang, Zhigang MB; Yu, Kai MB; Shang, Jinye MB; Zhou, Zhicong MB; Ma, Gang MM Author Information
Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate–conditioned Fanconi anemia mice
Authors: Asim Saha, Rahul Palchaudhuri, Leanne Lanieri, Sharon Hyzy, Megan J. Riddle, Jamie Panthera, Cindy R. Eide, Jakub Tolar, Angela Panoskaltsis-Mortari, Lev Gorfinkel, Victor Tkachev, Ulrike Gerdemann, Francesca Alvarez-Calderon, Elisa Rojas Palato, Margaret L. MacMillan, John E. Wagner, Leslie S. Kean, Mark J. Osborn, Hans-Peter Kiem, David T. Scadden, Lisa M. Olson, Bruce R. Blazar
Journal: Blood (2024)
Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
Authors: Johannes Lübke, Deborah Christen, Juliana Schwaab, Anne Kaiser, Nicole Naumann, Khalid Shoumariyeh, Madlen Jentzsch, Katja Sockel, Judith Schaffrath, Francis A. Ayuk, Matthias Stelljes, Inken Hilgendorf, Elisa Sala, Jennifer Kaivers, Stefan Schönland, Christoph Wittke, Bernd Hertenstein, Markus Radsak, Ulrich Kaiser, Valeska Brückl, Nicolaus Kröger, Tim H. Brümmendorf, Wolf-Karsten Hofmann, Stefan Klein, Edgar Jost, Andreas Reiter, Jens Panse
Journal: Leukemia (2024)

Abstract We identified 71 patients with AdvSM (aggressive SM [ASM], SM with an associated hematologic neoplasm [SM-AHN, e.g., acute myeloid leukemia, SM-AML], mast cell leukemia [MCL]) in two national registries (DRST/GREM) who received an allogeneic hematopoietic cell transplantation (alloHCT) performed in Germany from 1999–2021. Median overall survival (OS) of ASM/SM-AHN ( n = 30, 45%), SM-AML ( n = 28, 39%) and MCL ± AHN ( n = 13, 19%) was 9.0, 3.3 and 0.9 years ( P = 0.007). Improved median OS was associated with response of SM (17/41, 41%; HR 0.4 [0.2–0.9], P = 0.035) and/or of AHN (26/43, 60%, HR 0.3 [0.1–0.7], P = 0.004) prior to alloHCT. Adverse predictors for OS included absence of KIT D816V (10/61, 16%, HR 2.9 [1.2–6.5], P &lt; 0.001) and a complex karyotype (9/60, 15%, HR 4.2 [1.8–10.0], P = 0.016). HLA-match, conditioning type or transplantation at centers reporting above-average alloHCTs (≥7) had no impact on OS. Taking into account competing events at years 1, 3 and 5, relapse-related mortality and non-relapse mortality rate were 15%/23%, 20%/30% and 23%/35%, respectively. Irrespective of subtype, subsequent treatment response was achieved in 13/30 (43%) patients and was highest on midostaurin/avapritinib (7/9, 78%). We conclude that outcome of alloHCT in AdvSM is more affected by disease phenotype and treatment response prior to transplant than by transplant characteristics.
Differential Effects of JAK1 vs. JAK2 Inhibition in Mouse Models of Hemophagocytic Lymphohistiocytosis
Authors: Camille Keenan, Sabrin Albeituni, Ninad Oak, Alexa Stroh, Heather S. Tillman, Yingzhe Wang, Burgess B. Freeman, Silvia Alemán-Arteaga, Lauren K. Meyer, Rolanda Woods, Katherine C. Verbist, Yinmei Zhou, Cheng Cheng, Kim E. Nichols
Journal: Blood (2024)
Chimpanzees use social information to acquire a skill they fail to innovate
Authors: Edwin J. C. van Leeuwen, Sarah E. DeTroy, Daniel B. M. Haun, Josep Call
Journal: Nature Human Behaviour (2024)

Abstract Cumulative cultural evolution has been claimed to be a uniquely human phenomenon pivotal to the biological success of our species. One plausible condition for cumulative cultural evolution to emerge is individuals’ ability to use social learning to acquire know-how that they cannot easily innovate by themselves. It has been suggested that chimpanzees may be capable of such know-how social learning, but this assertion remains largely untested. Here we show that chimpanzees use social learning to acquire a skill that they failed to independently innovate. By teaching chimpanzees how to solve a sequential task (one chimpanzee in each of the two tested groups, n = 66) and using network-based diffusion analysis, we found that 14 naive chimpanzees learned to operate a puzzle box that they failed to operate during the preceding three months of exposure to all necessary materials. In conjunction, we present evidence for the hypothesis that social learning in chimpanzees is necessary and sufficient to acquire a new, complex skill after the initial innovation.
Indoor Temperature and Energy Insecurity: Implications for Prenatal Health Disparities in Extreme Heat Events
Authors: Gabriella Y. Meltzer, Pam Factor-Litvak, Julie B. Herbstman, Blair J. Wylie, Diana Hernández
Journal: Environmental Health Perspectives (2024)

Extreme heat events are a major public health concern and are only expected to increase in intensity and severity as climate change continues to accelerate. Pregnant people are physiologically more vulnerable to the effects of extreme heat, and exposure can induce harm on both the pregnant person and the fetus.
Publisher Correction: A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Authors: Marc Ferrell, Zeneng Wang, James T Anderson, Xinmin S Li, Marco Witkowski, Joseph A DiDonato, James R Hilser, Jaana A Hartiala, Arash Haghikia, Tomas Cajka, Oliver Fiehn, Naseer Sangwan, Ilja Demuth, Maximilian König, Elisabeth Steinhagen-Thiessen, Ulf Landmesser, W H Wilson Tang, Hooman Allayee, Stanley L Hazen
Journal: Nature Medicine (2024)
In situ injectable hydrogel encapsulating Mn/NO-based immune nano-activator for prevention of postoperative tumor recurrence
Authors: Shengnan Huang, Chenyang Zhou, Chengzhi Song, Xiali Zhu, Mingsan Miao, Chunming Li, Shaofeng Duan, Yurong Hu
Journal: Asian Journal of Pharmaceutical Sciences (2024)

Postoperative tumor recurrence remains a predominant cause of treatment failure. In this study, we developed an in situ injectable hydrogel, termed MPB-NO@DOX + ATRA gel, which was locally formed within the tumor resection cavity. The MPB-NO@DOX + ATRA gel was fabricated by mixing a thrombin solution, a fibrinogen solution containing all-trans retinoic acid (ATRA), and a Mn/NO-based immune nano-activator termed MPB-NO@DOX. ATRA promoted the differentiation of cancer stem cells, inhibited cancer cell migration, and affected the polarization of tumor-associated macrophages. The outer MnO2 shell disintegrated due to its reaction with glutathione and hydrogen peroxide in the cytoplasm to release Mn2+ and produce O2, resulting in the release of doxorubicin (DOX). The released DOX entered the nucleus and destroyed DNA, and the fragmented DNA cooperated with Mn2+ to activate the cGAS-STING pathway and stimulate an anti-tumor immune response. In addition, when MPB-NO@DOX was exposed to 808 nm laser irradiation, the Fe-NO bond was broken to release NO, which downregulated the expression of PD-L1 on the surface of tumor cells and reversed the immunosuppressive tumor microenvironment. In conclusion, the MPB-NO@DOX + ATRA gel exhibited excellent anti-tumor efficacy. The results of this study demonstrated the great potential of in situ injectable hydrogels in preventing postoperative tumor recurrence.
Circulating hematopoietic stem/progenitor cell subsets contribute to human hematopoietic homeostasis
Authors: Pamela Quaranta, Luca Basso-Ricci, Raisa Jofra Hernandez, Guido Pacini, Matteo Maria Naldini, Matteo Barcella, Luca Seffin, Giulia Pais, Giulio Spinozzi, Fabrizio Benedicenti, Carlo Pietrasanta, Jin Gyu Cheong, Andrea Ronchi, Lorenza Pugni, Francesca Dionisio, Ilaria Monti, Stefania Giannelli, Silvia Darin, Federico Fraschetta, Graziano Barera, Francesca Ferrua, Valeria Calbi, Marco Ometti, Raffaella Di Micco, Fabio Mosca, Steven Zvi Josefowicz, Eugenio Montini, Andrea Calabria, Maria Ester Bernardo, Maria Pia Cicalese, Bernhard Gentner, Ivan Merelli, Alessandro Aiuti, Serena Scala
Journal: Blood (2024)

Abstract In physiological conditions, few circulating hematopoietic stem/progenitor cells (cHSPCs) are present in the peripheral blood, but their contribution to human hematopoiesis remain unsolved. By integrating advanced immunophenotyping, single-cell transcriptional and functional profiling, and integration site (IS) clonal tracking, we unveiled the biological properties and the transcriptional features of human cHSPC subpopulations in relationship to their bone marrow (BM) counterpart. We found that cHSPCs reduced in cell count over aging and are enriched for primitive, lymphoid, and erythroid subpopulations, showing preactivated transcriptional and functional state. Moreover, cHSPCs have low expression of multiple BM-retention molecules but maintain their homing potential after xenotransplantation. By generating a comprehensive human organ-resident HSPC data set based on single-cell RNA sequencing data, we detected organ-specific seeding properties of the distinct trafficking HSPC subpopulations. Notably, circulating multi-lymphoid progenitors are primed for seeding the thymus and actively contribute to T-cell production. Human clonal tracking data from patients receiving gene therapy (GT) also showed that cHSPCs connect distant BM niches and participate in steady-state hematopoietic production, with primitive cHSPCs having the highest recirculation capability to travel in and out of the BM. Finally, in case of hematopoietic impairment, cHSPCs composition reflects the BM-HSPC content and might represent a biomarker of the BM state for clinical and research purposes. Overall, our comprehensive work unveiled fundamental insights into the in vivo dynamics of human HSPC trafficking and its role in sustaining hematopoietic homeostasis. GT patients’ clinical trials were registered at ClinicalTrials.gov (NCT01515462 and NCT03837483) and EudraCT (2009-017346-32 and 2018-003842-18).
NADPH oxidase exerts a B cell–intrinsic contribution to lupus risk by modulating endosomal TLR signals
Authors: Shuozhi Liu, Jonathan Lagos, Natali M. Shumlak, Andrea D. Largent, Sebastien T.E. Lewis, Ursula Holder, Samuel W. Du, Yifan Liu, Baidong Hou, Mridu Acharya, Shaun W. Jackson
Journal: The Journal of Experimental Medicine (2024)

Genome-wide association studies in systemic lupus erythematosus (SLE) have linked loss-of-function mutations in phagocytic NADPH oxidase complex (NOX2) genes, including NCF1 and NCF2, to disease pathogenesis. The prevailing model holds that reduced NOX2 activity promotes SLE via defective efferocytosis, the immunologically silent clearance of apoptotic cells. Here, we describe a parallel B cell–intrinsic mechanism contributing to breaks in tolerance. In keeping with an important role for B cell Toll-like receptor (TLR) pathways in lupus pathogenesis, NOX2-deficient B cells exhibit enhanced signaling downstream of endosomal TLRs, increased humoral responses to nucleic acid-containing antigens, and the propensity toward humoral autoimmunity. Mechanistically, TLR-dependent NOX2 activation promotes LC3-mediated maturation of TLR-containing endosomes, resulting in signal termination. CRISPR-mediated disruption of NCF1 confirmed a direct role for NOX2 in regulating endosomal TLR signaling in primary human B cells. Together, these data highlight a new B cell–specific mechanism contributing to autoimmune risk in NCF1 and NCF2 variant carriers.
Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia
Authors: Sudipta Sen, Paul P. Potnuru, Nadia Hernandez, Christina Goehl, Caroline Praestholm, Srikanth Sridhar, Omonele O. Nwokolo
Journal: JAMA Surgery (2024)

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is rapidly increasing in the US, driven by its expanded approval for weight management in addition to hyperglycemia management in patients with type 2 diabetes. The perioperative safety of these medications, particularly with aspiration risk under anesthesia, is uncertain.
Leveraging Continuous Glucose Monitors to Reduce the Risk of Diabetic Retinopathy
Authors: Estelle M. Everett
Journal: JAMA Network Open (2024)

T. Y. Alvin Liu, MD; Julia Shpigel; Fatima Khan; Kerry Smith, MS; Laura Prichett, MPH, PhD; Roomasa Channa, MD; Sarah Kanbour, MD; Marissa Jones, BS; Mohammed S. Abusamaan, MD, MPH; Aniket Sidhaye, MD; Nestoras Mathioudakis, MD, MHS; Risa M. Wolf, MD
More Than 40% of US Adults Know Someone Who Died of Drug Overdose
Authors: Emily Harris
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Use of Diabetes Technologies and Retinopathy in Adults With Type 1 Diabetes
Authors: T. Y. Alvin Liu, Julia Shpigel, Fatima Khan, Kerry Smith, Laura Prichett, Roomasa Channa, Sarah Kanbour, Marissa Jones, Mohammed S. Abusamaan, Aniket Sidhaye, Nestoras Mathioudakis, Risa M. Wolf
Journal: JAMA Network Open (2024)

Importance Diabetic retinopathy (DR) is a complication of diabetes that can lead to vision loss. Outcomes of continuous glucose monitoring (CGM) and insulin pump use in DR are not well understood. Objective To assess the use of CGM, insulin pump, or both, and DR and proliferative diabetic retinopathy (PDR) in adults with type 1 diabetes (T1D). Design, Setting, and Participants A retrospective cohort study of adults with T1D in a tertiary diabetes center and ophthalmology center was conducted from 2013 to 2021, with data analysis performed from June 2022 to April 2023. Exposure Use of diabetes technologies, including insulin pump, CGM, and both CGM and insulin pump. Main Outcomes and Measures The primary outcome was development of DR or PDR. A secondary outcome was the progression of DR for patients in the longitudinal cohort. Multivariable logistic regression models assessed for development of DR and PDR and association with CGM and insulin pump use. Results A total of 550 adults with T1D were included (median age, 40 [IQR, 28-54] years; 54.4% female; 24.5% Black or African American; and 68.4% White), with a median duration of diabetes of 20 (IQR, 10-30) years, and median hemoglobin A 1c (HbA 1c ) of 7.8% (IQR, 7.0%-8.9%). Overall, 62.7% patients used CGM, 58.2% used an insulin pump, and 47.5% used both; 44% (244 of 550) of the participants had DR at any point during the study. On univariate analysis, CGM use was associated with lower odds of DR and PDR, and CGM with pump was associated with lower odds of PDR (all P &amp;amp;lt; .05), compared with no CGM use. Multivariable logistic regression adjusting for age, sex, race and ethnicity, diabetes duration, microvascular and macrovascular complications, insurance type, and mean HbA 1c , showed that CGM was associated with lower odds of DR (odds ratio [OR], 0.52; 95% CI, 0.32-0.84; P = .008) and PDR (OR, 0.42; 95% CI, 0.23-0.75; P = .004), compared with no CGM use. In the longitudinal analysis of participants without baseline PDR, 79 of 363 patients (21.8%) had progression of DR during the study. Conclusions and Relevance In this cohort study of adults with T1D, CGM use was associated with lower odds of developing DR and PDR, even after adjusting for HbA 1c . These findings suggest that CGM may be useful for diabetes management to mitigate risk for DR and PDR.